Search Results

The Viramed Biotech AG Borrelia All-In-One ViraChip is an in vitro qualitative microarray assay for the detection of IgM and IgG antibodies to Borrelia burgdorferi in human serum. The assay is intended for testing serum samples from symptomatic patients or those suspected of Lyme Disease. It is intended to detect antibodies to VIsE and multiple other B. burgdorferi antigens following a modified two-tier test methodology. Positive results from the Viramed Biotech AG Borrelia All-In-One ViraChip are supportive evidence for the presence of antibodies and exposure to B. burgdorferi, the causative agent for Lyme disease. Negative results do not preclude infection with B. burgdorferi. Test results are to be used in conjunction with information obtained from the patient's clinical evaluation and other diagnostic procedures as an aid in diagnosis of Lyme disease.

The Viramed Biotech AG Borrelia All-In-One ViraChip Test must be used with a ViraChip Reader and the ViraChip Software.

Not Found

This document is an FDA 510(k) clearance letter for a medical device. It does not contain the detailed performance study results, acceptance criteria, or ground truth establishment methods as requested. The letter only states that the device is substantially equivalent to a predicate device and provides its indications for use.

Therefore, I cannot extract the information to complete the table and answer your questions directly from the provided text. The document clearly states "We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent...". This implies that the detailed study information would be in the 510(k) submission itself, not in the clearance letter.

Ask a specific question about this device